Home  »  Finance   »  Right Now May Be the Best Buy-In Window for Agile ...

Right Now May Be the Best Buy-In Window for Agile Therapeutics Inc. (AGRX)

Agile Therapeutics Inc. (AGRX) is priced at $0.30 after the most recent trading session. At the very opening of the session, the stock price was $0.3412 and reached a high price of $0.3449, prior to closing the session it reached the value of $0.34. The stock touched a low price of $0.2822.Recently in News on September 6, 2022, Agile Therapeutics to Present at the H.C. Wainwright 24th Annual Global Investment Conference. Agile Therapeutics, Inc. (Nasdaq: AGRX), a women’s healthcare company, announced that Chairman and Chief Executive Officer Al Altomari and Vice President of Marketing Amy Welsh will present at the H.C. Wainwright 24th Annual Global Investment Conference taking place September 12-14, 2022 in New York, NY. Details on the Company presentation are as follows:. You can read further details here

Agile Therapeutics Inc. had a pretty Dodgy run when it comes to the market performance. The 1-year high price for the company’s stock is recorded $21.3400 on 01/03/22, with the lowest value was $0.2822 for the same time period, recorded on 09/22/22.

Top 5 Cheap Stocks to Own Right Now

While finding safe stocks with the potential for monster gains isn't always easy, we've found a few that could pay out well. In fact, within our report, "Top 5 Cheap Stock to Own Right Now", we have identified five stocks we believe could appreciate the most even if you just have $1,000 to invest.

Sign up here to get your free report now. .


Agile Therapeutics Inc. (AGRX) full year performance was -99.27%

Price records that include history of low and high prices in the period of 52 weeks can tell a lot about the stock’s existing status and the future performance. Presently, Agile Therapeutics Inc. shares are logging -99.29% during the 52-week period from high price, and -9.75% higher than the lowest price point for the same timeframe. The stock’s price range for the 52-week period managed to maintain the performance between $0.34 and $42.40.

The company’s shares, operating in the sector of Healthcare managed to top a trading volume set approximately around 2368946 for the day, which was evidently lower, when compared to the average daily volumes of the shares.

When it comes to the year-to-date metrics, the Agile Therapeutics Inc. (AGRX) recorded performance in the market was -98.45%, having the revenues showcasing -74.77% on a quarterly basis in comparison with the same period year before. At the time of this writing, the total market value of the company is set at 65.76M, as it employees total of 30 workers.

Analysts verdict on Agile Therapeutics Inc. (AGRX)

According to the data provided on Barchart.com, the moving average of the company in the 100-day period was set at 0.9053, with a change in the price was noted -1.99. In a similar fashion, Agile Therapeutics Inc. posted a movement of -86.78% for the period of last 100 days, recording 7,476,491 in trading volumes.

Total Debt to Equity Ratio (D/E) can also provide valuable insight into the company’s financial health and market status. The debt to equity ratio can be calculated by dividing the present total liabilities of a company by shareholders’ equity. Debt to Equity thus makes a valuable metrics that describes the debt, company is using in order to support assets, correlating with the value of shareholders’ equity The total Debt to Equity ratio for AGRX is recording 3.71 at the time of this writing. In addition, long term Debt to Equity ratio is set at 0.00.

Agile Therapeutics Inc. (AGRX): Technical Analysis

Raw Stochastic average of Agile Therapeutics Inc. in the period of last 50 days is set at 4.22%. The result represents downgrade in oppose to Raw Stochastic average for the period of the last 20 days, recording 11.11%. In the last 20 days, the company’s Stochastic %K was 6.87% and its Stochastic %D was recorded 5.48%.

Let’s take a glance in the erstwhile performances of Agile Therapeutics Inc., multiple moving trends are noted. Year-to-date Price performance of the company’s stock appears to be encouraging, given the fact the metric is recording -98.45%. Additionally, trading for the stock in the period of the last six months notably deteriorated by -97.14%, alongside a downfall of -99.27% for the period of the last 12 months. The shares increased approximately by -24.30% in the 7-day charts and went up by -34.63% in the period of the last 30 days. Common stock shares were lifted by -74.77% during last recorded quarter.

Leave a Comment

Your email address will not be published.

On Key

Related Posts